Palisade Bio (PALI) Enterprise Value (2021 - 2026)

Palisade Bio (PALI) has reported Enterprise Value for 17 consecutive years, with -$132.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 1734.41% year-over-year to -$132.6 million; the TTM figure through Mar 2026 stood at -$132.6 million (down 1734.41% YoY), while the FY2025 annual figure was -$132.4 million, down 1256.13% from the prior year.
• Enterprise Value steadied at -$132.6 million in Q1 2026 per PALI's latest filing, from -$132.4 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$5.0 million in Q2 2022 and bottomed at -$132.6 million in Q1 2026.
• Historically, Enterprise Value has averaged -$24.6 million across 5 years, with a median of -$11.4 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 60.64% — and 2026, when it sank 1734.41%.
• Palisade Bio's Enterprise Value stood at -$12.4 million in 2022, then fell by 0.4% to -$12.4 million in 2023, then climbed by 21.47% to -$9.8 million in 2024, then slumped by 1256.13% to -$132.4 million in 2025, then retreated by 0.17% to -$132.6 million in 2026.
• Business Quant data shows PALI's Enterprise Value at -$132.6 million in Q1 2026, -$132.4 million in Q4 2025, and -$5.2 million in Q3 2025.